Avid Bioservices Inc (CDMO)

[Dragon Lady]

AZN DEAD for now, 10-K :

PAGE 4, 10-K:

"Collaboration with AstraZeneca Combining Bavituximab and Durvalumab (MEDI4736)

In August 2015, we entered into our first clinical collaboration with AstraZeneca to evaluate the combination of bavituximab and durvalumab (MEDI4736), an anti-PD-L1 monoclonal antibody, with chemotherapy in a planned Phase I/Ib trial in multiple solid tumors. In October 2015, we expanded our clinical collaboration with AstraZeneca to evaluate the combination of bavituximab and durvalumab in a Phase II study in patients with previously-treated squamous or non-squamous non-small cell lung cancer (“NSCLC”).

As discussed above, in June 2016, we announced a shift in corporate strategy to focus exclusively on small, early stage clinical trials combining bavituximab with immune stimulating therapies. For this reason, we will not proceed with any previously planned Phase II clinical trials. We are currently conducting an extensive review and analysis of the available clinical data and testing the numerous collected biomarkers samples in order to determine if certain subgroups or other patient characteristics benefited more from bavituximab. We believe such information will be critical in helping guide the bavituximab clinical program including our collaboration with AstraZeneca.
"

So that whole myth of the AZN "big deal" and "buyout" or "major partnership" or whatever- it just got tanked, sent to the sidelines too, looks like to me. NO phase II AZN trial. Kaput. Over. NO MORE. AZN is now in the "on deck" circle with all the other supposed "potential, maybe" ole "micro trials" that "might" start by 2017 or whatever, LOL !!

Another BUST on that one. Add to long list. Next....